Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 177

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 177
---
 thereafter.

Interests of the Directors and Executive Officers in the Liquidation

Some of our directors and executive officers may have interests in the Liquidation that are different from, or in addition to, the interests of
our Shareholders generally, namely, the Company’s continuing indemnification obligations to its directors and officers. While our executive officers may be entitled to certain change in control payments or benefits in connection with the
Arrangement, the Liquidation will not give rise to any incremental compensation, severance or change in control benefits for our directors or executive officers.

111

Common Share Ownership

Members of the Board and our executive officers own, as of November 21, 2025, the Record Date, an aggregate of 5,734,455 Common Shares
representing 13.3% of the outstanding Common Shares. In connection with any Liquidation distributions, certain of our directors and our executive officers will be entitled to the same pro rata cash distributions as our Shareholders based on their
ownership of Common Shares. See the section entitled “Security Ownership of Certain Beneficial Owners and Management” of this Circular and Proxy Statement for a table setting forth the number of Common Shares of the Company
beneficially owned by each of our directors and executive officers as of November 21, 2025.

Indemnification of Directors and Officers

If the Company proceeds with the Liquidation, the Company will continue, until the completion of the Liquidation, to indemnify and
provide for advancement of expenses to its officers, directors, employees, agents and representatives in accordance with the Company’s organizational documents, any contractual arrangements and applicable Law, for acts or omissions of such
persons in connection with the implementation of the Liquidation and the winding up of the affairs of the Company. The Company’s obligation to indemnify (or advance expenses to) such persons may also be satisfied out of insurance proceeds.

The Board or any trustee(s) or agent(s) as may be appointed by the Board in connection with the Liquidation, as applicable, is authorized
to obtain and maintain insurance as may be necessary, appropriate or desirable to cover the Company’s obligations in connection with the Liquidation, including its existing directors’ and officers’ liability insurance policy or any
replacement policy.

Consequences if the Liquidation is not Approved

IF THE LIQUIDATION RESOLUTION AND THE LIQUIDATOR RESOLUTION ARE NOT APPROVED AND THE ARRANGEMENT IS TERMINATED, THE FUTURE OF THE COMPANY WILL BE UNCERTAIN, AND ANY